Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile
about
Development of acute myocardial infarction in a young female patient with essential thrombocythemia treated with anagrelide: a case reportHeadache in essential thrombocythaemiaThe Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential ThrombocythemiaAnagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologistsDiagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of ThroPharmacological management of essential thrombocythemia.Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.Stress cardiomyopathy complicated by left ventricular thrombi and cerebral infarctions in a patient with essential thrombocythemia.Ruxolitinib for myelofibrosis.Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.Anagrelide: 20 years later.Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.Treatment options for essential thrombocythemia and polycythemia vera.Advances and challenges in the management of essential thrombocythemia.Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.Management of thrombocythemia.Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.The emergence of non-secretory multiple myeloma during the non-cytotoxic treatment of essential thrombocythemia: a case report.Ruxolitinib for the treatment of myelofibrosis: its clinical potential.Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia.Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.
P2860
Q24604097-B14DCF19-2268-49E0-88D9-B3E12A7E3CB5Q24629739-5B9DBECA-768C-4209-BFDF-85EC4502915CQ28074777-54A29F5B-4945-41FB-8E81-CF69BD526BB6Q28307195-CC3DF921-234E-43BF-9516-11335B8080ACQ30315531-CFF59AC7-E691-4EEA-97FE-7F28391D852EQ34344384-7849E174-EB76-4D50-A41B-1E8CB693F037Q34516397-082071B8-F53A-40BE-A868-7A3F0D4956EEQ35148803-E3486BF8-504D-49A7-8D14-A6AEB386F5ADQ36604028-26709074-C682-4DC7-87EF-91AA4C5F40B1Q36666769-D1163C2B-8C8C-448F-BC1C-94847C4822F9Q37357291-1AABA554-75D4-4256-857F-8B8376B626FFQ37810089-5D4DE23C-6A10-4EAA-B61C-8F2C6274CB32Q37810107-F0C797B3-4CF1-40D3-AF3F-138E9E0C1387Q38542093-215F5BD6-7ED7-46FA-A095-2F29F1F26858Q38586505-3DA94FAE-CC53-4435-BF05-804A053B6BA2Q39111631-9FEAE2F9-743D-47A6-AAB1-A244A947A1D0Q39456996-6AED7720-AB37-4AC6-BCD2-52DF616C3355Q39869975-721ACB34-B78F-4052-9FB3-4DACD662E98FQ42061288-FB08B056-58A1-4175-BC51-7CD52CB5D6FFQ42090824-547EF6DF-2DA2-4F4A-A971-B2386DCCD109Q42685892-7CCC28A4-FA40-49B5-85CD-4E84FB0FB6CAQ54262553-B8D767DF-7712-45F6-9878-3371F3DDB4F7Q54282327-582B76D1-77EA-429C-A5CC-EF441A613E7D
P2860
Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Anagrelide for thrombocytosis ...... cacy and adverse event profile
@ast
Anagrelide for thrombocytosis ...... cacy and adverse event profile
@en
Anagrelide for thrombocytosis ...... cacy and adverse event profile
@nl
type
label
Anagrelide for thrombocytosis ...... cacy and adverse event profile
@ast
Anagrelide for thrombocytosis ...... cacy and adverse event profile
@en
Anagrelide for thrombocytosis ...... cacy and adverse event profile
@nl
prefLabel
Anagrelide for thrombocytosis ...... cacy and adverse event profile
@ast
Anagrelide for thrombocytosis ...... cacy and adverse event profile
@en
Anagrelide for thrombocytosis ...... cacy and adverse event profile
@nl
P2093
P2860
P3181
P356
P1433
P1476
Anagrelide for thrombocytosis ...... cacy and adverse event profile
@en
P2093
Ernst Schlögl
Guenther Gastl
Michael Steurer
Robert Pytlik
Werner Lin
Wieslaw-Wiktor Jedrzejczak
P2860
P304
P3181
P356
10.1002/CNCR.20646
P407
P577
2004-11-15T00:00:00Z